Allogene upgraded to Outperform from Market Perform at Citizens JMP
Citizens JMP analyst Reni Benjamin upgraded Allogene Therapeutics (ALLO) to Outperform from Market Perform with a $5 price target The firm ...
Regenxbio price target raised to $24 from $22 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Regenxbio (RGNX) to $24 from $22 and keeps an Overweight rating on the ...
marketindex13h
Market Statistics
125 Years of the Australian Stock Market A breakdown of the Australian stock market’s historical returns since 1900. Presented in an easy-to-digest visual layout. Updated January 2025.